MDS Nordion signs 17-year contract with Rosenergoatom



    Contract expansion provides for increased cobalt-60 supply for the
    healthcare industry

    OTTAWA, Oct. 19 /CNW/ - MDS Nordion, a leading provider of medical
isotopes and radiopharmaceuticals, signed a 17-year contract for the supply of
cobalt-60 with Rosenergoatom, the operating utility of Russia's nuclear power
plants. This contract expands upon the 2005 agreement by providing for an
increased supply of cobalt-60 to MDS Nordion until 2024. As a result, MDS
Nordion's overall supply will increase by approximately 30% by 2016. Cobalt-60
is primarily used for the sterilization of hospital medical supplies and
pharmaceuticals to help prevent patient infection and disease by reducing
harmful bacteria.
    "As demand for cobalt-60 increases each year, this contract is great news
for the global medical community," said Steve West, President, MDS Nordion.
"It demonstrates MDS Nordion's ongoing commitment to provide customers a
long-term supply to meet their growing sterilization needs."
    Cobalt-60 is used worldwide to sterilize 45% of all disposable medical
devices such as surgeons' gloves, syringes, sutures, and catheters. This
sterilization process has been used for more than 40 years, having been proven
safe, reliable and highly effective.
    "Rosenergoatom plays an important role in providing a consistent supply
of cobalt-60," remarks Valery Lebedev, a Deputy Director General at
Rosenergoatom. "Unlike most power reactors, Rosenergoatom can harvest
cobalt-60 while the reactor is in operation. This allows MDS Nordion to more
closely match cobalt-60 supply to customer demand by increasing the
reliability and efficiency of the overall supply chain."

    About MDS Nordion

    MDS Nordion (www.mdsnordion.com) is a world leader in medical isotopes,
radiation and related technologies. It is a business unit of MDS Inc.
(TSX:MDS)(NYSE:  MDZ). MDS Inc. is a global life sciences company that provides
market-leading products and services for the development of drugs and
diagnosis and treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS Inc. has more than 6,200
highly skilled people in 28 countries. Find out more at www.mdsinc.com or by
calling 1-888-MDS-7222, 24 hours a day.

    About Rosenergoatom

    Rosenergoatom was established by the decree of the President of the
Russian Federation on September 7th, 1992 as the operating utility of Russia's
nuclear power plants. Rosenergoatom operates all 10 state-owned Russian
nuclear power facilities with a total of 31 nuclear reactors and an installed
electrical capacity of 23,242 Megawatts. Rosenergoatom has also increased
electric and thermal power output and recently commissioned two new power
reactors; Volgodonsk-1 and Kalinin-3. More information may be found at
http://www.rosenergoatom.ru/eng/.





For further information:

For further information: Media: Shelley Maclean, Manager External
Communications, MDS Nordion, (613) 592-3400 ext. 2414,
shelley.maclean@mdsinc.com; Investors: Sharon Mathers, Senior Vice-President,
Investor Relations and External Communications, MDS Inc., (416) 675-6777 x
34721, sharon.mathers@mdsinc.com

Organization Profile

MDS NORDION

More on this organization

Nordion Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890